U. Liberman, S. Weiss, J. Broll, H. Minne, H. Quan et al., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, N Engl J Med, issue.22, pp.3331437-3331480, 1995.

D. Black, S. Cummings, D. Karpf, J. Cauley, D. Thompson et al., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, The Lancet, vol.348, issue.9041, pp.1535-1576, 1996.
DOI : 10.1016/S0140-6736(96)07088-2

P. Meunier, P. Delmas, R. Eastell, M. Mcclung, S. Papapoulos et al., Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines, Clinical Therapeutics, vol.21, issue.6, pp.1025-1069, 1999.
DOI : 10.1016/S0149-2918(99)80022-8

G. Owens, R. Jackson, and E. Lewiecki, An integrated approach: bisphosphonate management for the treatment of osteoporosis, Am J Manag Care, vol.13, issue.S11, pp.290-308, 2007.

F. Blotman, B. Cortet, P. Hilliquin, B. Avouac, F. Allaert et al., El Hasnaoui A: Characterisation of patients with postmenopausal osteoporosis in French primary healthcare, Drugs Aging, issue.7, pp.24603-24617, 2007.

J. Kanis and C. Glüer, An Update on the Diagnosis and Assessment of Osteoporosis with Densitometry, Osteoporosis International, vol.11, issue.3, pp.192-202, 2000.
DOI : 10.1007/s001980050281

E. Lespessailles, F. Cotté, C. Roux, P. Fardellone, F. Mercier et al., Prevalence and features of osteoporosis in the French general population: The Instant study, Joint Bone Spine, vol.76, issue.4, pp.394-400, 2009.
DOI : 10.1016/j.jbspin.2008.10.008

S. Silverman and D. Gold, Compliance and persistence with osteoporosis therapies, Current Rheumatology Reports, vol.100, issue.Suppl2, pp.118-140, 2008.
DOI : 10.1007/s11926-008-0021-x

J. Cramer, N. Lynch, A. Gaudin, M. Walker, and W. Cowell, The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France, Clinical Therapeutics, vol.28, issue.10, pp.281686-94, 2006.
DOI : 10.1016/j.clinthera.2006.10.013

F. Lekkerkerker, J. Kanis, G. Bouvenot, N. Burlet, D. Cahall et al., Adherence to treatment of osteoporosis: a need for study, Osteoporosis International, vol.39, issue.suppl, pp.181311-181328, 2007.
DOI : 10.1007/s00198-007-0410-4

J. Cramer, A. Roy, A. Burrell, C. Fairchild, M. Fuldeore et al., Medication Compliance and Persistence: Terminology and Definitions, Value in Health, vol.11, issue.1, pp.44-47, 2008.
DOI : 10.1111/j.1524-4733.2007.00213.x

D. Hughes, A. Bagust, A. Haycox, and T. Walley, The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature, Health Economics, vol.283, issue.7, pp.601-616, 2001.
DOI : 10.1002/hec.609

D. Hughes, W. Cowell, T. Koncz, and J. Cramer, Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations, Value in Health, vol.10, issue.6, pp.498-509, 2007.
DOI : 10.1111/j.1524-4733.2007.00205.x

F. Cotté, B. Fautrel, D. Pouvourville, and G. , A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis, Medical Decision Making, vol.29, issue.1, pp.125-164, 2009.
DOI : 10.1177/0272989X08318461

D. Gold, B. Martin, J. Frytak, M. Amonkar, and F. Cosman, A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis, Current Medical Research and Opinion, vol.23, issue.3, pp.585-94, 2007.
DOI : 10.1185/030079906X167615

C. Van-den-boogaard, N. Breekveldt-postma, S. Borggreve, W. Goettsch, and R. Herings, Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study, Current Medical Research and Opinion, vol.22, issue.9, pp.1757-64, 2006.
DOI : 10.1185/030079906X132370

F. Cotté, F. Mercier, D. Pouvourville, and G. , Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: A retrospective case???control analysis, Clinical Therapeutics, vol.30, issue.12, pp.302410-2422, 2008.
DOI : 10.1016/j.clinthera.2008.12.019

J. Caro, K. Ishak, K. Huybrechts, G. Raggio, and C. Naujoks, The impact of compliance with osteoporosis therapy on fracture rates in actual practice, Osteoporosis International, vol.45, issue.12, pp.1003-1011, 2004.
DOI : 10.1007/s00198-004-1652-z

S. Cummings and L. Melton, Epidemiology and outcomes of osteoporotic fractures, The Lancet, vol.359, issue.9319, pp.1761-1768, 2002.
DOI : 10.1016/S0140-6736(02)08657-9

F. Cotté, B. Cortet, A. Lafuma, B. Avouac, A. Hasnaoui et al., A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France, Joint Bone Spine, vol.75, issue.2, pp.75201-75209, 2008.
DOI : 10.1016/j.jbspin.2007.06.004

C. Klotzbuecher, P. Ross, P. Landsman, T. Abbott, and M. Berger, Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis, Journal of Bone and Mineral Research, vol.318, issue.Suppl 5, pp.721-760, 2000.
DOI : 10.1359/jbmr.2000.15.4.721

J. Kanis, J. Brazier, M. Stevenson, N. Calvert, L. Jones et al., Treatment of established osteoporosis: a systematic review and cost-utility analysis, Health Technology Assessment, vol.6, issue.29, pp.1-146, 2002.
DOI : 10.3310/hta6290

Y. Bagger, L. Tanko, P. Alexandersen, P. Ravn, and C. Christiansen, Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal, Bone, vol.33, issue.3, pp.301-308, 2003.
DOI : 10.1016/S8756-3282(03)00112-1

P. Fardellone, A. Gaudin, F. Cotté, A. Lafuma, and C. Marchand, El Hasnaoui A: Comparaison of the persistance of daily and weekly bisphosphonates in Cotté and De Pouvourville BMC Health Services Research, pp.1472-6963, 2011.

A. Ismail, O. Neill, T. Cooper, C. Finn, J. Bhalla et al., Mortality Associated with Vertebral Deformity in Men and Women: Results from the European Prospective Osteoporosis Study (EPOS), Osteoporosis International, vol.8, issue.3, pp.291-298, 1998.
DOI : 10.1007/s001980050067

N. Shortt and C. Robinson, Mortality After Low-Energy Fractures in Patients Aged at Least 45 Years Old, Journal of Orthopaedic Trauma, vol.19, issue.6, pp.396-400, 2005.
DOI : 10.1097/01.bot.0000155311.04886.7e

S. Bouée, A. Lafuma, F. Fagnani, P. Meunier, and J. Reginster, Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries, Rheumatology International, vol.115, issue.8, pp.1063-72, 2006.
DOI : 10.1007/s00296-006-0180-x

J. Kanis, E. Mccloskey, H. Johansson, O. Strom, F. Borgstrom et al., National Osteoporosis Guideline Group: Case finding for the management of osteoporosis with FRAX?assessment and intervention thresholds for the UK, Osteoporos Int, issue.10, pp.191395-408, 2008.

R. Chapurlat and P. Delmas, Drug Insight: bisphosphonates for postmenopausal osteoporosis, Nature Clinical Practice Endocrinology & Metabolism, vol.20, issue.4, pp.211-220, 2006.
DOI : 10.1038/ncpendmet0121

S. Epstein, M. Jeglitsch, and E. Mccloskey, Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150???mg and risedronate 150???mg, Current Medical Research and Opinion, vol.25, issue.12, pp.2951-60, 2009.
DOI : 10.1185/03007990903361307

F. Cotté, P. Fardellone, F. Mercier, A. Gaudin, and C. Roux, Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis, Osteoporosis International, vol.23, issue.1, pp.145-55, 2010.
DOI : 10.1007/s00198-009-0930-1

V. Breuil, B. Cortet, F. Cotté, B. Arnould, C. Dias-barbosa et al., Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women, Osteoporosis International, vol.54, issue.2, 2011.
DOI : 10.1007/s00198-011-1555-8

G. Liu, E. Franssen, M. Fitch, and E. Warner, Patient preferences for oral versus intravenous palliative chemotherapy., Journal of Clinical Oncology, vol.15, issue.1, pp.110-115, 1997.
DOI : 10.1200/JCO.1997.15.1.110

S. Sullivan, D. Kreling, and T. Hazlet, Non-compliance with medication regimens and subsequent hospitalization: A literature analysis and cost of hospitalization estimate, J Res Pharm Econ, vol.2, pp.19-33, 1990.

A. Lewis, Noncompliance: a $100 billion problem, Remington Report, vol.5, pp.14-19, 1997.

M. Dimatteo, Variations in Patients??? Adherence to Medical Recommendations, Medical Care, vol.42, issue.3, pp.200-209, 2004.
DOI : 10.1097/01.mlr.0000114908.90348.f9

K. Davis, H. Edin, and J. Allen, Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data, Movement Disorders, vol.20, issue.Suppl 1, pp.474-80, 2010.
DOI : 10.1002/mds.22999

K. Davis, S. Candrilli, and H. Edin, Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population, Epilepsia, vol.11, issue.7, pp.446-54, 2008.
DOI : 10.1111/j.1528-1167.2007.01414.x

I. Cleemput, K. Kesteloot, Y. Vanrenterghem, D. Geest, and S. , The Economic Implications of Non-Adherence after Renal Transplantation, PharmacoEconomics, vol.21, issue.6, pp.1217-1251, 2004.
DOI : 10.2165/00019053-200422180-00006

J. Munakata, J. Benner, S. Becker, C. Dezii, E. Hazard et al., Clinical and Economic Outcomes of Nonadherence to Highly Active Antiretroviral Therapy in Patients With Human Immunodeficiency Virus, Medical Care, vol.44, issue.10, pp.44893-44902, 2006.
DOI : 10.1097/01.mlr.0000233679.20898.e9

S. Cherry, J. Benner, M. Hussein, S. Tang, and M. Nichol, The Clinical and Economic Burden of Nonadherence with Antihypertensive and Lipid-Lowering Therapy in Hypertensive Patients, Value in Health, vol.12, issue.4, pp.489-97, 2009.
DOI : 10.1111/j.1524-4733.2008.00447.x

J. Damen, P. Thuresson, B. Heeg, and M. Lothgren, A Pharmacoeconomic analysis of compliance gains on antipsychotic medications, Applied Health Economics and Health Policy, vol.108, issue.6, pp.189-97, 2008.
DOI : 10.1007/BF03256133

R. Windsor, W. Bailey, J. Richards, B. Manzella, S. Soong et al., Evaluation of the efficacy and cost effectiveness of health education methods to increase medication adherence among adults with asthma., American Journal of Public Health, vol.80, issue.12
DOI : 10.2105/AJPH.80.12.1519

J. Mckenney, Patient education and compliance: how to make it costeffective? Value Health, pp.212-217, 1998.